INS and metabolic dysfunction-associated steatotic liver disease: In general, the proposed mechanism explaining the action of SGLT-2 inhibitors in NAFLD/NASH is based on the reduction of plasma glucose due to glucosuria, and reversal of glucotoxicity, as well as reductions in circulating insulin and body weight.